Shah A K, Wei G, Lanman R C, Bhargava V O, Weir S J
Pfizer Inc., Central Research Division, Groton, Connecticut 06340, USA.
Pharm Res. 1996 Jan;13(1):168-72. doi: 10.1023/a:1016014308638.
The purpose of this study was to investigate the percutaneous absorption of ketoprofen applied topically to different anatomical sites on the body.
The study design was a randomized, four-way crossover in 24 healthy male subjects. One gram of ketoprofen 3% gel (30 mg dose) was applied every six hours for 25 doses over a 100 cm2 of the back, arm, and knee. A 0.5 ml of ketoprofen solution (60 mg/ml) was applied to the back as a reference treatment. Plasma and urine samples were obtained for the assay of racemic ketoprofen and ketoprofen enantiomers (S and R), respectively.
The relative bioavailabilities of ketoprofen gel were 0.90 +/- 0.50, 1.08 +/- 0.63, and 0.74 +/- 0.38 when applied to the back, arm, and knee, respectively. The plasma ketoprofen C(max) for gel applied to the back and arm are similar (p > 0.05) but C(max) was lower when applied to the knee (p < 0.05). The time to C(max) ranged from 2.7 to 4.0 hours and was similar for gel treatments on the back and arm, but no longer for the knee treatment. The fraction of dose excreted in urine as total S and R enantiomers ranged from 5.41 to 9.10%.
The percutaneous absorption of ketoprofen was similar when applied to either the back or arm but was lower when applied to the knee.
本研究旨在调查酮洛芬局部应用于身体不同解剖部位时的经皮吸收情况。
本研究设计为对24名健康男性受试者进行的随机、四交叉试验。将1克3%酮洛芬凝胶(剂量为30毫克)每6小时涂抹于背部、手臂和膝盖100平方厘米的面积上,共涂抹25次。将0.5毫升酮洛芬溶液(60毫克/毫升)涂抹于背部作为对照治疗。分别采集血浆和尿液样本,用于测定消旋酮洛芬和酮洛芬对映体(S型和R型)。
酮洛芬凝胶分别应用于背部、手臂和膝盖时,其相对生物利用度分别为0.90±0.50、1.08±0.63和0.74±0.38。应用于背部和手臂的凝胶的血浆酮洛芬C(max)相似(p>0.05),但应用于膝盖时C(max)较低(p<0.05)。达到C(max)的时间为2.7至4.0小时,背部和手臂的凝胶治疗相似,但膝盖治疗的时间更长。以总S型和R型对映体形式经尿液排泄的剂量分数为5.41%至9.10%。
酮洛芬应用于背部或手臂时的经皮吸收相似,但应用于膝盖时较低。